Atai Life Sciences

ATAI

This biopharmaceutical company develops psychedelic-based treatments and mental health medicines for patients with neurological and psychiatric disorders, such as treatment-resistant depression and anxiety.

Mindstate Design Labs

This biotechnology company develops custom psychedelic therapeutics using an artificial intelligence platform to treat mental health conditions for patients with various psychiatric disorders.

Small Pharma Limited

This clinical-stage biotechnology company develops psychedelic-based medicines and DMT therapies for patients with major depressive disorder and other mental health conditions.

Reunion Neuroscience

This biopharmaceutical company develops psychedelic-inspired therapeutic solutions for patients with underserved mental health disorders, such as postpartum depression and anxiety.

GH Research

This pharmaceutical company develops psychedelic-based therapies for patients suffering from psychiatric and neurological disorders, including treatment-resistant depression.

MindMed (NASDAQ: MNMD)

This biopharmaceutical company develops psychedelic-derived therapies to treat patients with brain health conditions, including anxiety, depression, and autism spectrum disorders.

Compass Pathways

This biotechnology company develops psilocybin-based therapies for patients living with treatment-resistant depression and other mental health conditions.

Enabling psychedelics-assisted therapies

This biopharmaceutical company develops psychedelic-inspired medicines and a care delivery model to treat addiction for patients and healthcare providers.